Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease”.
Clinical Benefit
| Substantial |
Le service médical rendu par ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé est important.
|
Clinical Added Value
| no clinical added value |
ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé n'apporte pas d'amélioration du service médical rendu (ASMR V) par rapport aux autres bronchodilatateurs de longue durée d'action disponibles dans cette indication.
|
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
JNRyLrKRSVUTqhqu
